HAE - Haemonetics Corporation

NYSE - NYSE Delayed Price. Currency in USD

Haemonetics Corporation

400 Wood Road
Braintree, MA 02184
United States
781-848-7100
http://www.haemonetics.com

SectorHealthcare
IndustryMedical Instruments & Supplies
Full Time Employees3,216

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher SimonCEO, Pres & Director2.9MN/A1964
Mr. William P. BurkeCFO & Exec. VP1.23M1.19M1968
Mr. Said Bolorforosh Ph.D.Exec. VP & CTO1.02MN/A1962
Ms. Michelle L. BasilExec. VP, Gen. Counsel & Sec.1.04MN/A1972
Ms. Jacqueline D. ScanlanSr. VP of Global HR873.58k299.63k1973
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through Japan, EMEA, North America Plasma, and All Other segments. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables, such as plasma collection containers and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

Corporate Governance

Haemonetics Corporation’s ISS Governance QualityScore as of October 4, 2019 is 2. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 5; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.